revumenib (informs SNDX-62122) is a Syndax Pharmaceuticals Inc program in myelofibrosis. Its next catalyst is a Readout in Q4 2027. 1 FDA decision on record below.
All upcoming FDA decision dates on the 2026 PDUFA calendar
revumenib (informs SNDX-62122) is marketed as Revuforj (revumenib); the events below include those tracked under the brand name. Indication under review: Myelofibrosis. Sponsor: Syndax Pharmaceuticals Inc (SNDX). We track 2 catalyst events for this program: 1 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for revumenib (informs SNDX-62122) is a Readout in Q4 2027.
On Oct 24, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.
In our records revumenib (informs SNDX-62122) is under review or in development for Myelofibrosis.
Syndax Pharmaceuticals Inc (SNDX).
Yes. The FDA approved an application for revumenib (informs SNDX-62122) on Oct 24, 2025; the decision page linked above carries the source.
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.